Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s SFDA Lifts Drug License, Bans Principals Over Rabies Vaccine

This article was originally published in PharmAsia News

Executive Summary

China's State FDA has found the general manager of Dalian Jingang-Andi Bio-products responsible for the decision to add nucleic acid to the production of human rabies vaccines to lower production costs. The agency also lifted the drug maker's production license and barred its principals from involvement in the pharmaceutical industry for the next 10 years. SFDA emphasized it has not completed its investigation and could implicate still others in the scandal. Although nucleic acid is used as an adjuvant in anti-viral drugs produced in other countries, China has not approved its use in rabies vaccines. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts